Drug Profile
ATS 907
Alternative Names: ATS907Latest Information Update: 13 Aug 2015
Price :
$50
*
At a glance
- Originator Asahi Kasei
- Developer Altheos
- Class Antiglaucomas; Eye disorder therapies
- Mechanism of Action Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Glaucoma; Ocular hypertension
Most Recent Events
- 31 Aug 2012 Altheos completes a phase IIa trial in Glaucoma & Ocular hypertension in USA (NCT01668524)
- 16 Aug 2012 Phase-II clinical trials in Glaucoma in USA (Topical)
- 16 Aug 2012 Phase-II clinical trials in Ocular hypertension in USA (Topical)